Welcome to our dedicated page for Adma Biologics SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ADMA Biologics, Inc. (NASDAQ: ADMA) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated explanations to help interpret the information. ADMA is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases.
Through this page, users can review ADMA’s current and historical SEC filings, including Form 8-K reports that announce material events such as quarterly financial results and business updates. For example, an 8-K dated November 5, 2025, references a press release detailing financial results for the quarter ended September 30, 2025 and a related business update. Filings such as 10-K annual reports and 10-Q quarterly reports (when available) typically contain detailed information on revenue composition, operating segments such as ADMA BioManufacturing and Plasma Collection Centers, risk factors, and descriptions of products like ASCENIV, BIVIGAM and NABI-HB.
Stock Titan’s platform enhances these documents with AI-powered summaries that highlight key points, helping readers quickly understand complex regulatory language. Users can also track real-time updates as new filings are posted to the SEC’s EDGAR system, and review insider transaction disclosures on forms such as Form 4 when they are filed, to see reported trades by company officers and directors.
This SEC filings hub is intended for investors and researchers who want a structured view of ADMA’s regulatory reporting, including its financial performance communications, capital structure updates, and disclosures related to its plasma-derived biologics portfolio and manufacturing operations.
ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina had 20,362 shares of common stock withheld at $9.11 per share to cover taxes on vesting restricted stock units. These shares were retained by the company to satisfy mandatory tax withholding and were not sold in the open market.
After this tax-withholding disposition, she directly holds 446,238 shares of ADMA common stock. Footnotes indicate this total includes multiple blocks of unvested restricted stock units that vest in quarterly installments over four years and common shares from prior option exercises and net share settlements.
ADMA Biologics filed a current report to furnish a press release responding to a short seller report by Culper Research. The company states it refutes key allegations about its business practices, operations and immune globulin portfolio, especially regarding its ASCENIV therapy for immune-compromised patients.
ADMA highlights that demand and utilization for ASCENIV have grown steadily over the past two years and are at a record high, and that distributor stocking levels align with industry standards and ASCENIV’s long production cycle. The release also reiterates ASCENIV’s FDA-approved indication, manufacturing approach, patent protection and important safety warnings, and provides an overview of ADMA’s broader plasma-derived biologics portfolio and development pipeline.
ADMA Biologics Inc: The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock. The amendment states that, following an 01/12/2026 internal realignment, certain Vanguard subsidiaries now report holdings separately and The Vanguard Group no longer reports beneficial ownership of those subsidiary holdings.
The filing is an ownership clarification by an institutional investor and does not disclose purchases or sales of ADMA shares in this amendment.
ADMA Biologics director Lawrence P. Guiheen reported a mix of option exercises and charitable estate planning transactions. On March 13, 2026, he exercised stock options to acquire 30,000 shares of common stock at $3.66 per share, increasing his direct equity stake. On March 17, 2026, he made bona fide gifts totaling 60,000 shares of common stock, including 30,000 shares transferred directly and 30,000 shares gifted to the 2019 Guiheen Irrevocable Trust, over which he retains control but disclaims beneficial ownership except for any pecuniary interest. After these transactions, he holds 105,520 shares directly, with additional shares held indirectly through irrevocable trusts as described in the footnotes.
ADMA Biologics President and CEO Adam S. Grossman exercised stock options for 15,000 shares of common stock at $5.40 per share on March 16, 2026, then sold 21,000 shares of common stock at $15.16 per share in open-market transactions.
The filing shows these trades were effected under a Rule 10b5-1 trading plan entered into on November 14, 2025. After the transactions, Grossman holds 2,112,777 shares of ADMA Biologics common stock directly, while entities Areth, LLC and Hariden, LLC hold 1,143,426 and 580,957 shares indirectly associated with him.
ADMA Biologics submitted a Form 144 notice proposing the sale of Common Stock. The filing lists multiple blocks of restricted stock units scheduled to vest on specific dates, including 15,162 shares vesting 06/26/2024 and another 15,162 shares vesting 06/26/2025. The broker/agent listed is Fidelity Brokerage Services, LLC (10b5-1 Group).
ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina reported multiple stock transactions. She exercised stock options to acquire 10,096 shares of common stock at exercise prices ranging from $1.55 to $5.00 per share. In connection with restricted stock unit vesting, 14,294 shares were withheld to cover mandatory tax obligations, which did not involve open-market sales. She also transferred 91,266 shares and sold 10,096 shares of common stock at a weighted average price of $15.63 per share, both carried out under a court-approved divorce settlement. Following these transactions, she directly owned 466,600 shares of ADMA Biologics common stock.
ADMA Biologics President and CEO Adam S. Grossman reported tax-related share withholdings rather than market trades. On March 6–7, 2026, a total of 85,951 shares of Common Stock were withheld at $15.39 per share to satisfy mandatory tax obligations upon vesting of restricted stock units, as noted in the footnotes. After these withholdings, he directly held 2,118,777 shares of Common Stock. Separate holding entries show additional indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities over which he has control roles.
ADMA Biologics submitted a Form 144 reporting proposed sales of Common Stock tied to option exercises, all dated 03/09/2026. The submission lists five exercise lots: 2,500, 1,250, 2,646, 1,525, and 2,175 shares, each described as "Stock Option Exercise" with the original grant dates shown.
ADMA Biologics director-affiliated funds reported open-market purchases of common stock. Entities associated with director Steve Elms bought a total of 14,000 ADMA shares, with 7,000 shares purchased on March 5, 2026 at a weighted average price of $15.67 per share and 7,000 shares on March 6, 2026 at a weighted average price of $15.39 per share.
The filing notes these shares are held by Aisling Capital II LP and Aisling Arcturus Partners, LP, and that Mr. Elms may be deemed a beneficial owner through his roles at Aisling entities while disclaiming beneficial ownership except to the extent of his pecuniary interest. Following these transactions, Aisling-related entities reported 2,045,730 shares, while Mr. Elms also directly holds 87,330 shares and 10,690 restricted stock units that are scheduled to fully vest on February 9, 2027, subject to continued service.